Emcure Pharmaceuticals Limited has had its credit ratings reaffirmed by CARE Ratings Limited. The ratings apply to its bank facilities, with long-term facilities rated ‘CARE AA; Stable’ and short-term facilities rated ‘CARE A1+’. This reaffirmation reflects the company’s robust business profile, diversified revenue, and strong financial indicators, suggesting continued stability and growth prospects.
Emcure Pharmaceuticals Secures Credit Rating Reaffirmation
Emcure Pharmaceuticals Limited announced today that CARE Ratings Limited has reaffirmed its credit ratings for the company’s bank facilities. This significant development underscores Emcure’s strong financial health and stable operational performance. The reaffirmation comes as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Rating Details
The long-term bank facilities of Emcure Pharmaceuticals have been assigned a ‘CARE AA; Stable‘ rating. Furthermore, its short-term bank facilities have been reaffirmed with a ‘CARE A1+‘ rating. These ratings reflect the company’s sustained ability to meet its financial obligations and its robust creditworthiness in the market.
The ‘CARE AA; Stable‘ rating for long-term facilities, with an enhanced amount of ₹1,563.00 crore (originally ₹1,348.00 crore), highlights Emcure’s strong position and outlook for its longer-term borrowing. The ‘CARE AA; Stable‘ rating for long-term bank facilities, amounting to ₹785.00 crore (enhanced from ₹557.50 crore), further solidifies its stable financial standing. The short-term bank facilities, valued at ₹52.00 crore, have been rated ‘CARE A1+‘, indicating a very strong capacity for repayment of short-term obligations.
Rationale Behind Ratings
CARE Ratings cited Emcure’s healthy business risk profile, geographically diverse revenue base, leadership in key therapeutic segments, experienced management, and strong R&D capabilities as key drivers for the reaffirmation. The company’s reported revenue growth of ~18% in FY26, driven by strong international market performance, and an improved PBILDT margin to 20.0% in FY26 were also highlighted. Strategic partnerships, portfolio expansion, and advancements in its product pipeline are expected to further support Emcure’s growth and profitability.
Despite an increase in debt levels in FY26 and a recent acquisition, Emcure’s comfortable capital structure and debt coverage indicators remain robust. The company has also focused on sharpening its strategy by divesting its mRNA business to concentrate on biologics and biosimilars, demonstrating agile strategic management.
Source: BSE
